Bartusik-Aebisher Dorota, Rudy Izabela, Pięta Karolina, Aebisher David
Department of Biochemistry and General Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland.
Student Scientific Club of Biochemists URCell, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland.
Molecules. 2025 Aug 25;30(17):3485. doi: 10.3390/molecules30173485.
Neoplasms of the central nervous system (CNS) constitute a minor fraction of all malignant tumors. CNS accounts for approximately 4% of newly diagnosed oncological cases. Among primary CNS neoplasms, gliomas predominate, comprising nearly 90% of all malignant brain tumors, with Glioblastoma (GBM) representing the most prevalent and aggressive histological subtype. The earliest documented occurrences of GBM date back to the 19th century. Contemporary therapeutic modalities for GBM primarily involve maximal surgical resection, adjuvant radiotherapy, and systemic chemotherapy. However, the intrinsic heterogeneity of GBM poses a formidable obstacle to treatment efficacy. The immunosuppressive tumor microenvironment, coupled with the restrictive nature of the blood-brain barrier (BBB), significantly limits the intratumorally delivery of chemotherapeutic agents. The emergence of nanotechnology in the biomedical domain has been driven by the urgent need to develop more effective and targeted anticancer interventions. Optimizing therapeutic outcomes necessitates the concurrent application of multimodal strategies. This review emphasizes the Nano-Based Technology in GBM.
中枢神经系统（CNS）肿瘤在所有恶性肿瘤中占比很小。中枢神经系统约占新诊断肿瘤病例的4%。在原发性中枢神经系统肿瘤中，胶质瘤占主导地位，占所有恶性脑肿瘤的近90%，其中胶质母细胞瘤（GBM）是最常见且侵袭性最强的组织学亚型。最早有记录的胶质母细胞瘤病例可追溯到19世纪。目前胶质母细胞瘤的主要治疗方式包括最大限度的手术切除、辅助放疗和全身化疗。然而，胶质母细胞瘤的内在异质性对治疗效果构成了巨大障碍。免疫抑制性肿瘤微环境，再加上血脑屏障（BBB）的限制性，显著限制了化疗药物在肿瘤内的递送。生物医学领域纳米技术的出现是由于迫切需要开发更有效、更具针对性的抗癌干预措施。优化治疗效果需要同时应用多模式策略。本综述重点介绍了基于纳米技术在胶质母细胞瘤中的应用。
